retatrutide news recency 3 ๐จBreaking: Retatrutide's first Phase T2D data just dropped. โธ A1C: โ2.0% at 40 weeks โธ Weight: โ36.6 lbs (โ16.8%) at 12 mg โธ No weight loss plateau โ curve still descending New Phase 3 retatrutide data
Description
At this smaller dose, some patients were taking the medication on a five-day schedule instead of seven-days
Although these results are highly promising, long-term data including primary CV prevention populations and utilizing other SGLT2-I will be needed to fully assess the CV outcomes with this class of medications
Is acid reflux from GLP-1 related to constipation
doi: 10.1161/JAHA.122.027712
Capacity is being scaled from 40 million units in FY26 to 220 million in FY27
This side effect is generally temporary, dose-dependent, and reversible
